<DOC>
	<DOCNO>NCT00061568</DOCNO>
	<brief_summary>People severe congenital anemia , sickle cell anemia beta-thalassemia , cure bone marrow transplantation ( BMT ) . The procedure , however , limited child young age 16 risk low child adult . The purpose study explore use BMT regimen , instead chemotherapy , use low dose radiation , combine two immunosuppressive drug . This type BMT procedure describe nonmyeloablative , mean destroy patient bone marrow . It hop type BMT safe patient normally excluded procedure age reason . To participate study , patient must age 18 65 sibling well-matched stem-cell donor . Beyond standard BMT protocol , study participant undergo additional procedure . The donor receive G-CSF injection five day ; stem cell collect frozen one month prior BMT . Approximately one month later , patient give two immune-suppressing drug , Campath 1-H Sirolimus , well single low dose total body irradiation cell donor infuse . Prior participation study , patient undergo follow evaluation : physical exam , blood work , breathe test , heart-function test , chest sinus x-ray , bone-marrow sampling .</brief_summary>
	<brief_title>Improving Results Bone Marrow Transplantation Patients With Severe Congenital Anemias</brief_title>
	<detailed_description>Nonmyeloablative allogeneic peripheral blood stem cell ( PBSC ) transplant currently investigate phase I/II trial assess engraftment , efficacy , toxicity number transplant center . Preliminary data show high rate complete donor engraftment relatively low toxicity profile . The decreased risk transplant-related complication associate nonmyeloablative transplant expand eligibility patient nonmalignant hematological disorder curable allogeneic transplantation ; however , significant toxicity current regimen persists include severe graft-versus-host-disease ( GVHD ) lead significant morbidity mortality . Moreover , mixed chimerism show sufficient induce clinical remission child nonmalignant hematologic disorder undergoing conventional allogeneic transplantation . Therefore , new regimen need develop applicable patient non-malignant disorder graft vs. leukemia effect need , mixed chimerism sufficient disease amelioration . In protocol , propose transplantation patient severe beta-globin disorder include sickle cell disease ( SCD ) , beta-thalassemia , consider high risk complication ineligible standard BMT , allogeneic PBSCs HLA identical sibling use novel immunosuppressive regimen without myeloablation attempt decrease transplant relate morbidity/mortality . The low intensity nonmyeloablative conditioning regimen consist low dose radiation , Alemtuzumab ( Campath ) Sirolimus ( Rapamune ) strategy provide adequate immunosuppression allow sufficient engraftment clinical remission low risk GVHD development . T-cell replete , donor-derived , granulocyte colony stimulate factor ( filgrastim , G-CSF ) mobilize PBSCs use establish hematopoietic lymphoid reconstitution . The primary endpoint study treatment success one year , define full donor type hemoglobin hemoglobin electrophoresis patient SCD transfusion-independence patient beta-thalassemia . Other end point include degree donor-host chimerism necessary long-term graft survival disease amelioration , incidence acute chronic graft-vs-host disease ( GVHD ) , incidence graft rejection , transplant related morbidity , well disease-free overall survival .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Diamond-Blackfan</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Anemia , Hemolytic , Congenital</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>INCLUSION CRITERIA : RECIPIENTS : Must fulfill one disease category : DISEASE SPECIFIC : Patients sickle cell disease high risk disease relate morbidity mortality , define irreversible end organ damage ( A , B , C , D E ) potentially reversible complication ( ) ameliorate hydroxyurea ( F ) : A. Stroke define clinically significant neurologic event accompany infarct cerebral MRI OR abnormal transcranial Doppler examination ( great equal 200m/s ) ; OR B. Sickle cell relate renal insufficiency define creatinine level great equal 1.5 time upper limit normal kidney biopsy consistent sickle cell nephropathy OR nephritic syndrome OR creatinine clearance less 60mL/min/1.73m ( 2 ) patient less equal 16 year age less 50mL/min patient great equal 16 year age OR require peritoneal hemodialysis OR Age less equal 5 year age upper limit normal serum creatinine 0.8mg/dl Age great 5 year less equal 10 year age upper limit normal serum creatinine 1.0mg/dl Age great 10 year less equal 15 year agethe upper limit normal serum creatinine 1.2mg/dl Age great 15 year age upper limit normal serum creatinine 1.3mg/dl C. Tricuspid regurgitant jet velocity ( TRV ) great equal 2.5m/s patient great equal 18 year age least 3 week vaso occlusive crisis , OR D. Recurrent tricorporal praipism define least two episodes erection last great equal 4 hour involve corpus cavernosa corpus spongiosa , OR E. Sickle hepatopathy define EITHER ferritin great 100mcg/L OR direct bilirubin great 0.4 mg/dL baseline patient great equal 18 year age ; OR F. Any one complication : 1 . Vasoocclusive crisis : Eligible hydroxyurea least 3 hospital admission last year Eligible HSCT More 1 hospital admission per year maximal tolerate dose hydroxyurea 2 . Acute Chest Syndrome ( ACS ) : Eligible hydroxyurea : 2 prior ACS great 3 year age adequately treat asthma Eligible HSCT : ACS hydroxyurea* 3 . Osteonecrosis 2 joint : Eligible hydroxyurea : And significantly affect quality life Karnofsky score 5060 Eligible HSCT : And hydroxyurea* total hemoglobin increase le 1g/dL fetal hemoglobin increase less 2.5 time baseline level 4 . Red cell alloimmunization : Eligible hydroxyurea : Transfusion dependent Eligible HSCT : Total hemoglobin increase less htan 1 g/dL hydroxyurea* hydroxyurea maximum tolerate dose Patients betathalassemia grade 2 3 iron overload , determine presence 2 following : portal fibrosis liver biopsy inadequate chelation history ( defined failure maintain adequate compliance chelation desferoxamine initiate within 18 month first transfusion administer subcutaneously 810 hour least 5 day week ) Hepatomegaly great 2 cm costochondral margin NONDISEASE SPECIFIC : Ages great equal 4 year 6/6 HLA match family donor available Ability comprehend willing sign inform consent , assent obtain minor Negative serum betaHCG Pediatric patient less 16 year age must decline myeloablative bone marrow transplantation DONOR : 6/6 HLA identical family donor Weight great equal 20 kg ( far weight difference recipient donor exceed reasonable likelihood able obtain adequate cell dose donor within two aphereses ) Fit receive GCSF give peripheral blood stem cell ( adequate blood count , stable blood pressure , history stroke ) Ability comprehend willing sign inform consent ; assent obtain minor EXCLUSION CRITERIA : RECIPIENT : ( Any follow would exclude subject participate ) ECOG performance status 3 Lansky performance status less 40 . Diffusion capacity carbon monoxide ( DLCO ) less 40 % predict . ( corrected hemoglobin alveolar volume ) Baseline oxygen saturation le 85 % PaOa2 le 70 Left ventricular ejection fraction : le 40 % estimate ECHO . Transaminases great 5 time upper limit normal age Evidence uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical symptom ) within one month prior start condition regimen Major anticipate illness organ failure incompatible survival PBSC transplant . Pregnant lactate Major ABO mismatch DONOR : ( Any follow would exclude donor participate ) Pregnant lactate HIV positive Hemoglobin S great equal 50 % , betathalassemia intermedia</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 21, 2017</verification_date>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Low Dose Radiation</keyword>
	<keyword>Alemtuzumab ( Campath )</keyword>
	<keyword>Sirolimus ( Rapamune )</keyword>
	<keyword>Donor Apheresis</keyword>
	<keyword>Graft-Versus-Host Disease</keyword>
	<keyword>Graft-Versus-Marrow</keyword>
	<keyword>Host-Donor Chimerism</keyword>
	<keyword>Peripheral Blood Stem Cells</keyword>
	<keyword>Low Dose Irradiation</keyword>
	<keyword>Sickle Cell Anemia</keyword>
	<keyword>SCA</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Diamond-Blackfan Anemia</keyword>
	<keyword>DBA</keyword>
</DOC>